On the occasion of World Epilepsy Day (14th of February 2022), Angelini Pharma, international Italian pharmaceutical company, is committed to provide patients and healthcare professionals with innovative solutions improving the care of patients with epilepsy .
ONTOZRY™ (cenobamate) receives positive CHMP opinion for the adjunctive treatment of uncontrolled focal onset seizures in adults
January 29, 2021 12:20 ET | Source: Arvelle Therapeutics Arvelle Therapeutics
Positive CHMP opinion is an important milestone for Arvelle Therapeutics and cenobamate
When approved, cenobamate will provide new hope in helping adult patients with uncontrolled focal epilepsy move closer to the goal of seizure reduction and seizure freedom
ZUG, Switzerland, Jan. 29, 2021 (GLOBE NEWSWIRE) Arvelle Therapeutics, an emerging biopharmaceutical company focused on bringing innovative treatments to patients suffering from central nervous system (CNS) disorders, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of cenobamate for the